Lupin to market Forest's AeroChamber Plus in the US
This article was originally published in Scrip
Executive Summary
Lupinhas signed a multi-year agreement with Forest Laboratoriesto promote and market Forest's AeroChamber Plus line of products in the US. AeroChamber Plus is a valved holding chamber (VHC) device that is used with metered dose inhalers to improve the delivery of medication to the lungs in the treatment of asthma and chronic obstructive pulmonary disease. Lupin's US subsidiary will use its 50-person sales force to promote the product to paediatricians. The company also expects the alliance to help extend its presence in the respiratory segment and strengthen its franchise with paediatricians. AeroChamber Plus is the most widely prescribed holding chamber in the US and about two thirds of AeroChamber Plus VHC prescriptions (IMS 2007) are written by paediatricians.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.